<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127745">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872975</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP-B-51/RTOG-1304</org_study_id>
    <secondary_id>NCI-2012-03198</secondary_id>
    <secondary_id>U10CA012027</secondary_id>
    <nct_id>NCT01872975</nct_id>
  </id_info>
  <brief_title>Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery</brief_title>
  <official_title>A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Surgical Adjuvant Breast and Bowel Project (NSABP)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Surgical Adjuvant Breast and Bowel Project (NSABP)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies standard or comprehensive radiation therapy in
      treating patients with early-stage breast cancer who have undergone surgery. Radiation
      therapy uses high-energy x rays to kill tumor cells. It is not yet known whether
      comprehensive radiation therapy is more effective than standard radiation therapy in
      treating patients with breast cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      To evaluate whether the addition of chest wall + regional nodal radiation therapy (XRT)
      after mastectomy or breast + regional nodal XRT after breast conserving surgery will
      significantly reduce the rate of events for invasive breast cancer recurrence-free interval
      (IBC-RFI) in patients who present with histologically positive axillary nodes but convert to
      histologically negative axillary nodes following neoadjuvant chemotherapy.

      SECONDARY OBJECTIVES:

      I. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or
      breast + regional nodal XRT after breast conserving surgery will significantly prolong
      overall survival (OS) in patients who present with histologically positive axillary nodes
      but convert to histologically negative axillary nodes following neoadjuvant chemotherapy.

      II. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or
      breast + regional nodal XRT after breast conserving surgery will significantly reduce the
      rates of events for local-regional recurrence-free interval (LRRFI) in patients who present
      with histologically positive axillary nodes but convert to histologically negative axillary
      nodes following neoadjuvant chemotherapy.

      III. To evaluate whether the addition of chest wall + regional nodal XRT after mastectomy or
      breast + regional nodal XRT after breast conserving surgery will significantly reduce the
      rate of events for distant recurrence-free interval (DRFI) in patients who present with
      histologically positive axillary nodes but convert to histologically negative axillary nodes
      following neoadjuvant chemotherapy.

      IV. To compare the rates of disease-free survival (DFS)-ductal carcinoma in situ (DCIS) by
      treatment arm.

      V. To compare the rates of second primary cancer (SPC) by treatment arm.

      VI. To compare the effect of adding XRT on the cosmetic outcomes in mastectomy patients who
      have had reconstruction.

      VII. To compare the effect of adding XRT on quality of life including arm problems,
      lymphedema, pain, and fatigue.

      VIII. To evaluate the toxicity associated with each of the radiation therapy regimens.

      IX. To determine whether computed tomography (CT)-based conformal methods
      (intensity-modulated radiation therapy [IMRT] and 3-dimensional conformal radiation therapy
      [3DCRT]) for chestwall + regional nodal XRT post mastectomy and regional nodal XRT with
      breast XRT following breast conserving surgery are feasible in a multi-institutional setting
      and whether dose-volume analyses can be established to assess treatment adequacy and to
      develop normal tissue complication probabilities (NTCP) for the likelihood of toxicity.

      X. To compare the effect of XRT in patients receiving mastectomy and in patients receiving
      lumpectomy.

      XI. To examine the role of proliferation measures as a prognosticator for patients with
      residual disease after neoadjuvant chemotherapy.

      XII. To develop predictors of the degree of reduction in local regional recurrence (LRR).

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM 1: Patients are assigned to 1 of 2 treatment groups.

      GROUP 1A: Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3DCRT
      once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy
      cavity once daily 5 days a week for 1-1/2 weeks.

      GROUP 1B: Mastectomy patients do not undergo radiation therapy.

      ARM 2: Patients are assigned to 1 of 2 treatment groups.

      GROUP 2A: Lumpectomy patients undergo regional nodal radiation therapy with whole breast
      radiation therapy using IMRT or 3DCRT once daily 5 days a week for 5 weeks followed by a
      radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.

      GROUP 2B: Mastectomy patients undergo regional nodal radiation therapy and chestwall XRT
      using IMRT or 3DCRT once daily 5 days a week for 5 weeks.

      All patients also receive systemic therapy as planned (hormonal therapy for patients with
      hormone-receptor positive breast cancer and trastuzumab or other anti-human epidermal growth
      factor receptor 2 [HER2] therapy for patients with breast cancer that is HER2-positive).

      After completion of study treatment, patients are followed up at 6, 12, 18, and 24 months
      and then yearly for 8 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2028</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>IBC-RFI</measure>
    <time_frame>Time from randomization until invasive local, regional, or distant recurrence, or death from breast cancer, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Time from randomization to death from any cause, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LRRFI</measure>
    <time_frame>Time from randomization to recurrence of primary cancer w/in breast or lymph nodes in ipsilateral axilla, infraclavicular fossa, or ipsilateral internal mammary chain w/out evidence distant disease, or death due to breast cancer, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DRFI</measure>
    <time_frame>Time from randomization to the development of tumor in all areas beyond local or regional limits, or death due to breast cancer, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS-DCIS</measure>
    <time_frame>Time from randomization to local recurrence post-mastectomy/in ipsilateral breast post-lumpectomy, regional/distant recurrence, contralateral disease, second primary cancer, or death from any cause prior to recurrence or SPC, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to SPC</measure>
    <time_frame>Time from randomization to the development of a second primary invasive cancer of any site excluding squamous and basal cell carcinoma of the skin, assessed up to 10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of radiation therapy on cosmetic outcome in mastectomy and lumpectomy patients as assessed by quality of life questionnaire</measure>
    <time_frame>Assessed prior to randomization, 3 months or at end of RT, and 6, 12, and 24 months from randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequencies of adverse events graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular predictors of recurrence</measure>
    <time_frame>Tissue samples collected after randomizaiton; the gene expression profiles are measured at the end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>To test the prognostic role of gene expression profiles in residual tumor tissue and to develop predictors of the degree of reduction of loco-regional recurrence.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1636</enrollment>
  <condition>Stage IB Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1A Lumpectomy: no regional nodal XRT with WBI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B Mastectomy: No regional nodal or chestwall XRT</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Mastectomy patients do not undergo radiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A lumpectomy:  Regional nodal XRT with WBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lumpectomy patients undergo regional nodal radiation therapy with whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B Mastectomy:  Regional nodal XRT and chestwall XRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mastectomy patients undergo regional nodal radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>regional nodal XRT</intervention_name>
    <arm_group_label>Group 2A lumpectomy:  Regional nodal XRT with WBI</arm_group_label>
    <arm_group_label>Group 2B Mastectomy:  Regional nodal XRT and chestwall XRT</arm_group_label>
    <other_name>XRT: External radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chestwall XRT</intervention_name>
    <arm_group_label>Group 2B Mastectomy:  Regional nodal XRT and chestwall XRT</arm_group_label>
    <other_name>XRT:  External radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>WBI</intervention_name>
    <arm_group_label>Group 1A Lumpectomy: no regional nodal XRT with WBI</arm_group_label>
    <arm_group_label>Group 2A lumpectomy:  Regional nodal XRT with WBI</arm_group_label>
    <other_name>Whole Breast Irradiation (WBI)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have signed and dated an Institutional Review Board (IRB)-approved
             consent form that conforms to federal and institutional guidelines

          -  The patient must have an Eastern Cooperative Oncology Group (ECOG) performance status
             of 0 or 1

          -  Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before
             neoadjuvant therapy); clinical axillary nodal involvement can be assessed by
             palpation, ultrasound, CT scan, magnetic resonance imaging (MRI), positron emission
             tomography (PET) scan, or PET/CT scan

          -  Patient must have had pathologic confirmation of axillary nodal involvement at
             presentation (before neoadjuvant therapy) based on either a positive fine needle
             aspirate (FNA) (demonstrating malignant cells) or positive core needle biopsy
             (demonstrating invasive adenocarcinoma); the FNA or core needle biopsy can be
             performed either by palpation or by image guidance; documentation of axillary nodal
             positivity by sentinel node biopsy (before neoadjuvant therapy) is not permitted

          -  Patients must have had estrogen receptor (ER) analysis performed on the primary
             breast tumor before neoadjuvant therapy according to current American Society of
             Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline
             recommendations for hormone receptor testing; if negative for ER, assessment of
             progesterone receptor (PgR) must also be performed according to current ASCO/CAP
             guideline recommendations for hormone receptor testing (http://www.asco.org)

          -  Patients must have had HER2 testing performed on the primary breast tumor before
             neoadjuvant chemotherapy according to the current ASCO/CAP guideline recommendations
             for human epidermal growth factor receptor 2 testing in Breast Cancer
             (http://www.asco.org); patients who have a primary tumor that is either HER2-positive
             or HER2-negative are eligible

          -  Patient must have completed a minimum of 12 weeks of standard neoadjuvant
             chemotherapy consisting of an anthracycline and/or taxane-based regimen

          -  For patients who receive adjuvant chemotherapy after surgery, a maximum of 12 weeks
             of intended chemotherapy may be administered but must be completed before
             randomization; (if treatment delays occur, chemotherapy must be completed within 14
             weeks); the dose and schedule of the adjuvant chemotherapy are at the investigator's
             discretion; Note: It is preferred that all intended chemotherapy be administered in
             the neoadjuvant setting

          -  Patients with HER2-positive tumors must have received neoadjuvant trastuzumab or
             other anti-HER2 therapy (either with all or with a portion of the neoadjuvant
             chemotherapy regimen), unless medically contraindicated

          -  At the time of definitive surgery, all removed axillary nodes must be histologically
             free from cancer; acceptable procedures for assessment of axillary nodal status at
             the time of surgery include:

               -  Axillary node dissection

               -  Sentinel node biopsy alone or

               -  Sentinel node biopsy followed by axillary node dissection

               -  Note: Patients are eligible whether there is residual invasive carcinoma in the
                  surgical breast specimen or whether there is evidence of pathologic complete
                  response; patients who are found to be pathologically node-positive at the time
                  of surgery, based on sentinel node biopsy alone, are candidates for A011202, a
                  study developed by the Alliance in Oncology, an NCI Cooperative Group; if
                  A011202 is open at the investigator's institution, patients should be approached
                  about participating in the A011202 study

          -  Patients with pathologic staging of ypN0(i+) or ypN0(mol+) are eligible (Note:
             Postneoadjuvant therapy is designated with a &quot;yp&quot; prefix.)

          -  Patient who have undergone either a total mastectomy or a lumpectomy are eligible

          -  For patients who undergo lumpectomy, the margins of the resected specimen or
             re-excision must be histologically free of invasive tumor and DCIS as determined by
             the local pathologist; additional operative procedures may be performed to obtain
             clear margins; if tumor is still present at the resected margin after re-excision(s),
             the patient must undergo total mastectomy to be eligible; (patients with margins
             positive for lobular carcinoma in situ [LCIS] are eligible without additional
             resection)

          -  For patients who undergo mastectomy, the margins must be histologically free of
             residual (microscopic or gross) tumor

          -  The interval between the last surgery for breast cancer (including re-excision of
             margins) and randomization must be no more than 56 days; also, if adjuvant
             chemotherapy was administered, the interval between the last chemotherapy treatment
             and randomization must be no more than 56 days

          -  The patient must have recovered from surgery with the incision completely healed and
             no signs of infection

          -  If adjuvant chemotherapy was administered, chemotherapy-related toxicity that may
             interfere with delivery of radiation therapy should have resolved

        Exclusion Criteria:

          -  Definitive clinical or radiologic evidence of metastatic disease

          -  T4 tumors including inflammatory breast cancer

          -  Documentation of axillary nodal positivity before neoadjuvant therapy by sentinel
             node biopsy alone

          -  N2 or N3 disease detected clinically or by imaging

          -  Patients with histologically positive axillary nodes post neoadjuvant therapy

          -  Patients with microscopic positive margins after definitive surgery

          -  Synchronous or previous contralateral invasive breast cancer or DCIS; (patients with
             synchronous and/or previous contralateral LCIS are eligible)

          -  Any prior history, not including the index cancer, of ipsilateral invasive breast
             cancer or ipsilateral DCIS treated with radiation therapy; (patients with synchronous
             or previous ipsilateral LCIS are eligible)

          -  History of non-breast malignancies (except for in situ cancers treated only by local
             excision and basal cell and squamous cell carcinomas of the skin) within 5 years
             prior to randomization

          -  Any radiation therapy for the currently diagnosed breast cancer prior to
             randomization

          -  Any continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone
             replacement therapy; patients are eligible if these medications are discontinued
             prior to randomization

          -  Prior breast or thoracic radiation therapy (RT) for any condition

          -  Active collagen vascular disease, specifically dermatomyositis with a creatinine
             phosphokinase (CPK) level above normal or with an active skin rash, systemic lupus
             erythematosus, or scleroderma

          -  Pregnancy or lactation at the time of study entry; (Note: Pregnancy testing must be
             performed within 2 weeks prior to randomization according to institutional standards
             for women of childbearing potential)

          -  Other non-malignant systemic disease that would preclude the patient from receiving
             study treatment or would prevent required follow-up

          -  Psychiatric or addictive disorders or other conditions that, in the opinion of the
             investigator, would preclude the patient from meeting the study requirements
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Ketner</last_name>
    <phone>412-339-5345</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John R. Russell</last_name>
      <phone>877-904-4367</phone>
    </contact>
    <investigator>
      <last_name>John R. Russell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Alaska Medical Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne E. Anderson</last_name>
      <phone>907-261-3109</phone>
    </contact>
    <investigator>
      <last_name>Jeanne E. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates-West Orange Grove</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Cancer Center - North Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uma G. Swamy</last_name>
      <phone>559-447-4050</phone>
    </contact>
    <investigator>
      <last_name>Uma G. Swamy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Hospital - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A. Margileth</last_name>
      <phone>714-734-6220</phone>
    </contact>
    <investigator>
      <last_name>David A. Margileth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pomona Valley Hospital Medical Center</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yallapragada S. Rao</last_name>
      <phone>909-865-9555</phone>
    </contact>
    <investigator>
      <last_name>Yallapragada S. Rao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Fehrenbacher</last_name>
      <phone>626-564-3455</phone>
    </contact>
    <investigator>
      <last_name>Louis Fehrenbacher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyoti S. Mayadev</last_name>
      <phone>916-734-3089</phone>
    </contact>
    <investigator>
      <last_name>Jyoti S. Mayadev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-South San Francisco</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Fehrenbacher</last_name>
      <phone>626-564-3455</phone>
    </contact>
    <investigator>
      <last_name>Louis Fehrenbacher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen C. Horst</last_name>
      <phone>650-498-7061</phone>
      <email>ccto-office@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen C. Horst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Solano Medical Center</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari D. Baron</last_name>
      <phone>415-600-1182</phone>
      <email>SchmidtJ@cpmcri.org</email>
    </contact>
    <investigator>
      <last_name>Ari D. Baron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers-Boulder</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keren Sturtz</last_name>
      <phone>888-785-6789</phone>
    </contact>
    <investigator>
      <last_name>Keren Sturtz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Hospital Saint Raphael Campus</name>
      <address>
        <city>Hew Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne B. Evans</last_name>
      <phone>203-785-5702</phone>
    </contact>
    <investigator>
      <last_name>Suzanne B. Evans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital of Central Connecticut</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal B. Goldberg</last_name>
      <phone>860-224-5660</phone>
    </contact>
    <investigator>
      <last_name>Neal B. Goldberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne B. Evans</last_name>
      <phone>203-785-5702</phone>
    </contact>
    <investigator>
      <last_name>Suzanne B. Evans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John L. Zapas</last_name>
      <phone>443-777-7364</phone>
    </contact>
    <investigator>
      <last_name>John L. Zapas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System - Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srinath Sundararaman</last_name>
      <phone>954-265-2234</phone>
    </contact>
    <investigator>
      <last_name>Srinath Sundararaman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos A. Alemany</last_name>
      <phone>407-303-5623</phone>
    </contact>
    <investigator>
      <last_name>Carlos A. Alemany</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Dvorak</last_name>
      <phone>321-841-7246</phone>
    </contact>
    <investigator>
      <last_name>Tomas Dvorak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida-Putnam</name>
      <address>
        <city>Palatka</city>
        <state>Florida</state>
        <zip>32177</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas W. Johnson</last_name>
      <phone>904-202-7051</phone>
    </contact>
    <investigator>
      <last_name>Douglas W. Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mylin A. Torres</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Mylin A. Torres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mylin A. Torres</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Mylin A. Torres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam W. Nowlan</last_name>
      <phone>404-425-7943</phone>
      <email>phri@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Adam W. Nowlan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dekalb Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's-Candler Health System</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John A. Pablo</last_name>
      <phone>912-819-5704</phone>
    </contact>
    <investigator>
      <last_name>John A. Pablo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth N. Sumida</last_name>
      <phone>808-586-2979</phone>
      <email>dorothy@crch.hawaii.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth N. Sumida</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kootenai Cancer Center</name>
      <address>
        <city>Post Falls</city>
        <state>Idaho</state>
        <zip>83854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric D. Donnelly</last_name>
      <phone>312-695-1301</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Eric D. Donnelly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John H Stroger Jr Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3785</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas E. Lad</last_name>
      <phone>312-864-6000</phone>
    </contact>
    <investigator>
      <last_name>Thomas E. Lad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarita O. Thomas</last_name>
      <phone>708-226-4357</phone>
    </contact>
    <investigator>
      <last_name>Tarita O. Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nguyet A. Le-Lindqwister</last_name>
      <phone>800-793-2262</phone>
    </contact>
    <investigator>
      <last_name>Nguyet A. Le-Lindqwister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nguyet A. Le-Lindqwister</last_name>
      <phone>800-793-2262</phone>
    </contact>
    <investigator>
      <last_name>Nguyet A. Le-Lindqwister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Regional Cancer Care-East Radiation Oncology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih J. Wei</last_name>
      <phone>317-621-7104</phone>
    </contact>
    <investigator>
      <last_name>Shih J. Wei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Regional Cancer Care-North</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shih J. Wei</last_name>
      <phone>317-621-7104</phone>
    </contact>
    <investigator>
      <last_name>Shih J. Wei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bilal Ansari</last_name>
      <phone>574-237-1328</phone>
    </contact>
    <investigator>
      <last_name>Bilal Ansari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Thomas</last_name>
      <phone>800-237-1225</phone>
    </contact>
    <investigator>
      <last_name>Alexandra Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parvesh Kumar</last_name>
      <phone>913-588-4709</phone>
    </contact>
    <investigator>
      <last_name>Parvesh Kumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Centers-Southwest</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parvesh Kumar</last_name>
      <phone>913-588-4709</phone>
    </contact>
    <investigator>
      <last_name>Parvesh Kumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward H. Romond</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>Edward H. Romond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic CCOP</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mini J. Elnaggar</last_name>
      <phone>888-562-4763</phone>
    </contact>
    <investigator>
      <last_name>Mini J. Elnaggar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tate Cancer Center</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven J. Feigenberg</last_name>
      <phone>800-888-8823</phone>
    </contact>
    <investigator>
      <last_name>Steven J. Feigenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faina Nakhlis</last_name>
      <phone>617-983-7000</phone>
    </contact>
    <investigator>
      <last_name>Faina Nakhlis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas J. Doyle</last_name>
      <phone>313-916-1784</phone>
    </contact>
    <investigator>
      <last_name>Thomas J. Doyle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital-Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nayana S. Dekhne</last_name>
      <phone>248-551-7695</phone>
    </contact>
    <investigator>
      <last_name>Nayana S. Dekhne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Troy</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nayana S. Dekhne</last_name>
      <phone>248-551-7695</phone>
    </contact>
    <investigator>
      <last_name>Nayana S. Dekhne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott-Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert W. Mutter</last_name>
      <phone>507-538-7623</phone>
    </contact>
    <investigator>
      <last_name>Robert W. Mutter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick J. Flynn</last_name>
      <phone>952-993-1517</phone>
      <email>MMCCOP@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Flynn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Cancer Center - South</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parvesh Kumar</last_name>
      <phone>913-588-4709</phone>
    </contact>
    <investigator>
      <last_name>Parvesh Kumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital of Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Gaur</last_name>
      <phone>913-948-5588</phone>
      <email>aroland@kccop.org</email>
    </contact>
    <investigator>
      <last_name>Rakesh Gaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center-South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria A. Thomas</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Maria A. Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria A. Thomas</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Maria A. Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish West County Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria A. Thomas</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Maria A. Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - Saint Peters</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria A. Thomas</last_name>
      <phone>800-600-3606</phone>
      <email>info@siteman.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Maria A. Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kalispell Regional Medical Center</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin T. Marchello</last_name>
      <phone>800-648-6274</phone>
    </contact>
    <investigator>
      <last_name>Benjamin T. Marchello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan C. Hartford</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Alan C. Hartford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County</name>
      <address>
        <city>Mount Holly</city>
        <state>New Jersey</state>
        <zip>08060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <phone>888-847-8823</phone>
    </contact>
    <investigator>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura A. Klein</last_name>
      <phone>201-634-5792</phone>
    </contact>
    <investigator>
      <last_name>Laura A. Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparta Cancer Treatment Center</name>
      <address>
        <city>Sparta</city>
        <state>New Jersey</state>
        <zip>07871</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pramila R. Anne</last_name>
      <phone>215-955-6084</phone>
    </contact>
    <investigator>
      <last_name>Pramila R. Anne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virtua West Jersey Hospital Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <phone>888-847-8823</phone>
    </contact>
    <investigator>
      <last_name>Lemuel S. Ariaratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Imogene Bassett Hospital</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy E. Anderson</last_name>
      <phone>607-547-3073</phone>
      <email>diana.crean@bassett.org</email>
    </contact>
    <investigator>
      <last_name>Joy E. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy M. Zagar</last_name>
      <phone>877-668-0683</phone>
      <email>cancerclinicaltrials@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy M. Zagar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin P. Favaro</last_name>
      <phone>704-384-5369</phone>
    </contact>
    <investigator>
      <last_name>Justin P. Favaro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Atlantic Radiation Oncology</name>
      <address>
        <city>Supply</city>
        <state>North Carolina</state>
        <zip>28462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A. Papagikos</last_name>
      <phone>910-251-1839</phone>
    </contact>
    <investigator>
      <last_name>Michael A. Papagikos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Radiation Oncology</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A. Papagikos</last_name>
      <phone>910-251-1839</phone>
    </contact>
    <investigator>
      <last_name>Michael A. Papagikos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Bismarck Medical Center</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preston D. Steen</last_name>
      <phone>701-234-6161</phone>
    </contact>
    <investigator>
      <last_name>Preston D. Steen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Akron City Hospital/Cooper Cancer Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer E. Payne</last_name>
      <phone>330-375-6101</phone>
    </contact>
    <investigator>
      <last_name>Jennifer E. Payne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew H. Fenton</last_name>
      <phone>330-344-6348</phone>
    </contact>
    <investigator>
      <last_name>Andrew H. Fenton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Barberton Hospital</name>
      <address>
        <city>Barberton</city>
        <state>Ohio</state>
        <zip>44203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer E. Payne</last_name>
      <phone>330-375-6101</phone>
    </contact>
    <investigator>
      <last_name>Jennifer E. Payne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia R. White</last_name>
      <phone>866-627-7616</phone>
      <email>osu@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Julia R. White</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delaware Radiation Oncology</name>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John P. Kuebler</last_name>
      <phone>614-566-3275</phone>
    </contact>
    <investigator>
      <last_name>John P. Kuebler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summa Health Center at Lake Medina</name>
      <address>
        <city>Medina</city>
        <state>Ohio</state>
        <zip>44256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer E. Payne</last_name>
      <phone>330-375-6101</phone>
    </contact>
    <investigator>
      <last_name>Jennifer E. Payne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terence S. Herman</last_name>
      <phone>405-271-4272</phone>
      <email>julie-traylor@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Terence S. Herman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Natalie Warren Bryant Cancer Center at Saint Francis</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James B. Lockhart</last_name>
      <phone>918-494-2200</phone>
    </contact>
    <investigator>
      <last_name>James B. Lockhart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffery S. Eshleman</last_name>
      <phone>717-544-5511</phone>
    </contact>
    <investigator>
      <last_name>Jeffery S. Eshleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alle-Kiski Medical Center</name>
      <address>
        <city>Natrona Heights</city>
        <state>Pennsylvania</state>
        <zip>15065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas B. Julian</last_name>
      <phone>877-284-2000</phone>
    </contact>
    <investigator>
      <last_name>Thomas B. Julian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pramila R. Anne</last_name>
      <phone>215-955-6084</phone>
    </contact>
    <investigator>
      <last_name>Pramila R. Anne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Cancer Center at Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas B. Julian</last_name>
      <phone>877-284-2000</phone>
    </contact>
    <investigator>
      <last_name>Thomas B. Julian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Surgical Adjuvant Breast and Bowel Project</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212-5234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleftherios (Terry) P. Mamounas</last_name>
      <phone>330-438-6281</phone>
      <email>tmamounas@aultman.com</email>
    </contact>
    <investigator>
      <last_name>Eleftherios (Terry) P. Mamounas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reading Hospital</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terrence P. Cescon</last_name>
      <phone>610-988-9323</phone>
    </contact>
    <investigator>
      <last_name>Terrence P. Cescon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WellSpan Health-York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L. Eamonn Boyle</last_name>
      <phone>877-441-7957</phone>
    </contact>
    <investigator>
      <last_name>L. Eamonn Boyle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James M. Orcutt</last_name>
      <phone>843-720-8386</phone>
      <email>elizabeth.strojny@roperstfrancis.com</email>
    </contact>
    <investigator>
      <last_name>James M. Orcutt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Addison R. Tolentino</last_name>
      <phone>800-657-4377</phone>
      <email>Jan.Healy@avera.org</email>
    </contact>
    <investigator>
      <last_name>Addison R. Tolentino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel D. Scaperoth</last_name>
      <phone>865-541-1812</phone>
    </contact>
    <investigator>
      <last_name>Daniel D. Scaperoth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Arlington South</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA - Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Klabzuba Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Memorial City Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona F. Shaitelman</last_name>
      <phone>713-792-3245</phone>
    </contact>
    <investigator>
      <last_name>Simona F. Shaitelman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Round Rock Cancer Center</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cancer Center Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek S. Kavadi</last_name>
      <phone>281-277-5200</phone>
    </contact>
    <investigator>
      <last_name>Vivek S. Kavadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center-North</name>
      <address>
        <city>Saint Johnsbury</city>
        <state>Vermont</state>
        <zip>05819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan C. Hartford</last_name>
      <phone>800-639-6918</phone>
      <email>cancer.research.nurse@dartmouth.edu</email>
    </contact>
    <investigator>
      <last_name>Alan C. Hartford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry D. Bear</last_name>
      <phone>804-628-1939</phone>
    </contact>
    <investigator>
      <last_name>Harry D. Bear</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harrison Medical Center</name>
      <address>
        <city>Bremerton</city>
        <state>Washington</state>
        <zip>98310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya A. Wahl</last_name>
      <phone>425-688-5407</phone>
      <email>patra.grevstad@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Tanya A. Wahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Community Hospital</name>
      <address>
        <city>Puyallup</city>
        <state>Washington</state>
        <zip>98372</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshio Inoue</last_name>
      <phone>253-403-2394</phone>
    </contact>
    <investigator>
      <last_name>Yoshio Inoue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya A. Wahl</last_name>
      <phone>425-688-5407</phone>
      <email>patra.grevstad@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Tanya A. Wahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest - Spokane South</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya A. Wahl</last_name>
      <phone>425-688-5407</phone>
      <email>patra.grevstad@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Tanya A. Wahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multicare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshio Inoue</last_name>
      <phone>253-403-2394</phone>
    </contact>
    <investigator>
      <last_name>Yoshio Inoue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshio Inoue</last_name>
      <phone>253-403-2394</phone>
    </contact>
    <investigator>
      <last_name>Yoshio Inoue</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Valley Surgical Associates Limited</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Honnie R. Bermas</last_name>
      <phone>800-574-3872</phone>
    </contact>
    <investigator>
      <last_name>Honnie R. Bermas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Appleton Medical Center</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Editha (Edie) A. Krueger</last_name>
      <phone>920-380-1500</phone>
    </contact>
    <investigator>
      <last_name>Editha (Edie) A. Krueger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Hospital</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica A. Wernberg</last_name>
      <phone>715-389-4457</phone>
    </contact>
    <investigator>
      <last_name>Jessica A. Wernberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Oettel</last_name>
      <phone>608-775-2385</phone>
      <email>cancerctr@gundluth.org</email>
    </contact>
    <investigator>
      <last_name>Kurt Oettel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany M. Anderson</last_name>
      <phone>877-405-6866</phone>
    </contact>
    <investigator>
      <last_name>Bethany M. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica A. Wernberg</last_name>
      <phone>715-389-4457</phone>
    </contact>
    <investigator>
      <last_name>Jessica A. Wernberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Memorial Hospital</name>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <zip>53051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam D. Currey</last_name>
      <phone>414-805-4380</phone>
    </contact>
    <investigator>
      <last_name>Adam D. Currey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Saint Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell H. Pincus</last_name>
      <phone>800-252-2990</phone>
    </contact>
    <investigator>
      <last_name>Mitchell H. Pincus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam D. Currey</last_name>
      <phone>414-805-4380</phone>
    </contact>
    <investigator>
      <last_name>Adam D. Currey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic-Minocqua Center</name>
      <address>
        <city>Minocqua</city>
        <state>Wisconsin</state>
        <zip>54548</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica A. Wernberg</last_name>
      <phone>715-389-4457</phone>
    </contact>
    <investigator>
      <last_name>Jessica A. Wernberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic-Rice Lake Center</name>
      <address>
        <city>Rice Lake</city>
        <state>Wisconsin</state>
        <zip>54868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica A. Wernberg</last_name>
      <phone>715-389-4457</phone>
    </contact>
    <investigator>
      <last_name>Jessica A. Wernberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Hospital</name>
      <address>
        <city>Stevens Point</city>
        <state>Wisconsin</state>
        <zip>54481</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica A. Wernberg</last_name>
      <phone>715-389-4457</phone>
    </contact>
    <investigator>
      <last_name>Jessica A. Wernberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Medical Center in Summit</name>
      <address>
        <city>Summit</city>
        <state>Wisconsin</state>
        <zip>53066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell H. Pincus</last_name>
      <phone>800-252-2990</phone>
    </contact>
    <investigator>
      <last_name>Mitchell H. Pincus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care-Milwaukee West</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell H. Pincus</last_name>
      <phone>800-252-2990</phone>
    </contact>
    <investigator>
      <last_name>Mitchell H. Pincus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Yassa</last_name>
      <phone>514-252-3400ext3329</phone>
    </contact>
    <investigator>
      <last_name>Michael Yassa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard G. Margolese</last_name>
      <phone>514-340-8222ext8248</phone>
    </contact>
    <investigator>
      <last_name>Richard G. Margolese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>June 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
